AIMS: Vascular endothelial growth factor (VEGF) and pathologic angiogenesis have been demonstrated to play a pathogenic role in the development and progression of inflammatory bowel disease. Thus, we hypothesized that the potent anti-angiogenic factor endostatin might play a beneficial role in experimental ulcerative colitis (UC). MAIN METHODS: We used three animal models of UC: (1) induced by 6% iodoacetamide (IA) in rats, or (2) by 3% dextran sulfate sodium (DSS) in matrix metalloproteinase-9 (MMP-9) knockout (KO) and wild-type mice, and (3) interleukin-10 (IL-10) KO mice. Groups of MMP-9 KO mice with DSS-induced UC were treated with endostatin or water for 5days. KEY FINDINGS: We found concomitant upregulation of VEGF, PDGF, MMP-9 and endostatin in both rat and mouse models of UC. A positive correlation between the levels of endostatin or VEGF and the sizes of colonic lesions was seen in IA-induced UC. The levels and activities of MMP-9 were also significantly increased during UC induced by IA and IL-10 KO. Deletion of MMP-9 decreased the levels of endostatin in both water- and DSS-treated MMP-9 KO mice. Treatment with endostatin significantly improved DSS-induced UC in MMP-9 KO mice. SIGNIFICANCE: 1) Concomitantly increased endostatin is a defensive response to the increased VEGF in UC, 2) MMP-9 is a key enzyme to generate endostatin which may modulate the balance between VEGF and endostatin during experimental UC, and 3) endostatin treatment plays a beneficial role in UC. Thus, anti-angiogenesis seems to be a new therapeutic option for UC. Published by Elsevier Inc.
AIMS: Vascular endothelial growth factor (VEGF) and pathologic angiogenesis have been demonstrated to play a pathogenic role in the development and progression of inflammatory bowel disease. Thus, we hypothesized that the potent anti-angiogenic factor endostatin might play a beneficial role in experimental ulcerative colitis (UC). MAIN METHODS: We used three animal models of UC: (1) induced by 6% iodoacetamide (IA) in rats, or (2) by 3% dextran sulfate sodium (DSS) in matrix metalloproteinase-9 (MMP-9) knockout (KO) and wild-type mice, and (3) interleukin-10 (IL-10) KO mice. Groups of MMP-9 KO mice with DSS-induced UC were treated with endostatin or water for 5days. KEY FINDINGS: We found concomitant upregulation of VEGF, PDGF, MMP-9 and endostatin in both rat and mouse models of UC. A positive correlation between the levels of endostatin or VEGF and the sizes of colonic lesions was seen in IA-induced UC. The levels and activities of MMP-9 were also significantly increased during UC induced by IA and IL-10 KO. Deletion of MMP-9 decreased the levels of endostatin in both water- and DSS-treated MMP-9 KO mice. Treatment with endostatin significantly improved DSS-induced UC in MMP-9 KO mice. SIGNIFICANCE: 1) Concomitantly increased endostatin is a defensive response to the increased VEGF in UC, 2) MMP-9 is a key enzyme to generate endostatin which may modulate the balance between VEGF and endostatin during experimental UC, and 3) endostatin treatment plays a beneficial role in UC. Thus, anti-angiogenesis seems to be a new therapeutic option for UC. Published by Elsevier Inc.
Authors: J Spalinger; H Patriquin; M C Miron; G Marx; D Herzog; J Dubois; M Dubinsky; E G Seidman Journal: Radiology Date: 2000-12 Impact factor: 11.105
Authors: Vijay C Ganta; Walter Cromer; Ginny L Mills; James Traylor; Merilyn Jennings; Sarah Daley; Benjamin Clark; J Michael Mathis; Michael Bernas; Moheb Boktor; Paul Jordan; Marlys Witte; J Steven Alexander Journal: Inflamm Bowel Dis Date: 2010-06 Impact factor: 5.325
Authors: Salman Punekar; Samantha Zak; Valerie G Kalter; Larissa Dobransky; Imran Punekar; Jack W Lawler; Linda S Gutierrez Journal: Pathobiology Date: 2008-03-11 Impact factor: 4.342
Authors: Amir Abdollahi; Philip Hahnfeldt; Christian Maercker; Hermann-Josef Gröne; Juergen Debus; Wilhelm Ansorge; Judah Folkman; Lynn Hlatky; Peter E Huber Journal: Mol Cell Date: 2004-03-12 Impact factor: 17.970
Authors: Tejas M Shah; Jignasha G Patel; Tejas P Gohil; Damer P Blake; Chaitanya G Joshi Journal: NPJ Biofilms Microbiomes Date: 2019-09-20 Impact factor: 7.290